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Background: Nose breathing ensures that inspired air is warm, filtered and moist and may
therefore benefit patients with asthma. It features in some complementary approaches to
treat asthma and is encouraged at night in the Buteyko technique by the use of mouth taping.
In this pragmatic study we sought to determine whether taping the mouth at night has any
effect on asthma control compared with usual breathing in patients with symptomatic asthma,
since if it was effective it would be a simple intervention to implement.
Methods: This was a randomised, single-blind, crossover study of participants (nZ 51) with
symptomatic asthma (mean FEV1 86% predicted). A 4-week period of usual breathing at night
was followed by use of mouth taping with microporous tape, as in the Buteyko technique, or
vice versa, with a 2-week run-in period and a minimum 2-week washout period of usual
breathing between ‘treatments’. Primary outcomes were morning peak expiratory flow and
symptom scores (Asthma Control Diary). Outcomes were measured and analysed without
knowledge of treatment allocation.
Results: Fifty participants completed the study and reported taping their mouth for a median 26
of 28 nights. Although 36 participants said mouth taping was very or fairly acceptable there were
no differences between treatments for morning peak expiratory flow (mean difference1 l/min
(95%CI,9 to 7)) or symptoms scores (mean difference0.12 (95%CI,0.30 to 0.06)) nor for any
secondary measures.
Conclusions: Taping the mouth at night had no effect on asthma control in patients with symp-
tomatic asthma. (Registered: www.controlled-trials.com/ISRCTN74428617). Trial Registration
Number: ISRCTN74428617.
ª 2009 Elsevier Ltd. All rights reserved.y volume in one second; FVC, forced vital capacity; PEF, peak expiratory flow.
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Patients with asthma are interested in alternative
approaches to drug treatment to control their symptoms.1e4
The Buteyko technique is one such option and a number of
studies have shown a reduction in symptoms and b2-agonist
use following its introduction and at least a trend towards an
improvement in quality of life.5e10 The technique originated
in Russia but has been adapted in the West as a comple-
mentary package, involving various interventions including
breathing exercises to reduce respiratory rate and minute
volume, and breathing through the nose. To encourage nose
breathing at night, many Buteyko practitioners recommend
that patients tape their mouth with porous surgical tape.11
Nose breathing is also part of other breathing techniques
used for asthma including yoga12 and the Papworth method,
a physiotherapy technique originally developed to treat
hyperventilation.13
Although practitioners argue that all aspects of the
Buteyko technique are important, one component for
which there is clear rationale and some evidence, albeit
circumstantial, is nose breathing. Nose breathing ensures
inspired air is filtered and that the air is warm and moist, all
of which may benefit patients with asthma. Treating
allergic rhinitis and nasal polyps which should increase nose
breathing has led to improvement in asthma control,
bronchial responsiveness and the need for hospitalisation or
emergency room care.14e17
If taping the mouth at night improved asthma control in
patients with symptomatic asthma it would be a simple
intervention to implement. We therefore carried out
a pragmatic trial to assess asthma control when patients
taped theirmouth at night compared to their usual breathing
at night. Morning peak expiratory flow and symptom scores
(Asthma Control Diary) were the primary outcomemeasures.
Methods
Participants
Werecruited volunteers aged18e72with asthmabut noother
important illness between June 2004 and September 2006. To
be included participants had to be symptomatic, defined as
taking at least four puffs a week of an inhaled short-acting
bronchodilator, and have daily symptoms plus either
nocturnal or earlymorning symptoms or overnight fall in peak
expiratory flow (PEF) of 10% or more on at least 3 nights
a week during the run-in period. Other asthma medication
apart fromoral corticosteroidswasallowedproviding that the
dose was stable over the preceding four weeks. Participants
were excluded if they had a forced expiratory volume in one
second (FEV1) below 50% predicted, previous training in the
Buteyko technique, reported that they could not breathe
through their nose, had beendiagnosedwith sleep apnoea, or
had a smoking history of more than 10 pack years.
Nottingham Research Ethics Committee 1 approved the
study. Participants were recruited from our asthma volun-
teer database and from posters, electronic and newspaper
advertisements. These mentioned that we were looking to
see if breathing through the nose at night would have any
effect on asthma control. Participants received a patientinformation sheet and gave written informed consent. The
single centre study was undertaken in a university respira-
tory research department of a large teaching hospital in
Nottingham, UK.
Measurements
FEV1 and forced vital capacity (FVC) were measured with
a Fleisch type pneumotachograph spirometer (Vitalograph
Alpha, Buckingham, UK) with the participant seated, as the
best of two measurements within 100 ml.
Participants kept two daily diary cards with one (A)
being used to record the best of three morning and evening
peak expiratory flow measurements using a mini-Wright
peak flow meter (Clement Clarke International Ltd.), use of
bronchodilators (day and night), and symptoms using the
Juniper Asthma Control Diary questions.18 A separate diary
card (B) recorded how many hours the mouth tape was in
place plus any comments or problems with the treatment.
Three questionnaires were completed by the participant
at study visits: the Mini-Asthma Quality of Life Question-
naire19 which covers activity limitation, symptoms,
emotional function and exposure to environmental stimuli,
the Asthma Control Questionnaire20 which asks about
asthma symptoms and medication use, and the Nijmegen
questionnaire21 which asks about symptoms associated with
abnormal breathing patterns.
Protocol
The study used a crossover design with participants rand-
omised to usual breathing followed by use of mouth tape at
night, each for four weeks, or vice versa, with a minimum
two-week run-in period and a minimum two-week washout
period between treatments. Participants visited the
department on five occasions, at the same time of day for
a given participant (þ/ 1 h). They were asked to withhold
short-acting bronchodilators for at least 6 h before each
visit and long-acting bronchodilators for 24 h.
At the screening visit, participants were assessed for
eligibility, had FEV1 response to 400 mg salbutamol
measured and were asked questions about nasal symptoms,
their usual breathing route, nocturnal symptoms and
snoring. They were asked and given written instructions to
use short-acting bronchodilators only as required for
symptom relief, and were given diary cards and a peak flow
meter to use at home. The three quality of life question-
naires were completed and spirometry (FEV1 and FVC)
performed at this and each subsequent visit.
After the run-in, eligible participants were randomised
using a block design in groups of 10 with computer gener-
ated code supplied by a statistician. The Treatment Co-
ordinator showed them how to tape their mouth at night
with 2.5 cm wide microporous tape (Micropore) to facili-
tate nose breathing and suggested they practice this during
the daytime to ensure they could tolerate it. The mouth
taping technique used was as recommended by Buteyko
practitioners, including orientating the tape from nose to
chin. Participants were told that we were looking to see if
mouth taping made a difference to asthma control but not
what effect was anticipated.
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period participants were first seen by the Treatment Co-
ordinator who reviewed diary card B, recorded any prob-
lems with mouth taping, and, at the end of the study, asked
the participant to complete a questionnaire about accept-
ability and treatment preference. Participants were asked
to contact the Treatment Co-ordinator with any queries or
problems with taping and told not to tell the Assessor when
they were using mouth tape. The tape does not generally
leave any visible marks when removed. The Assessor, who
was not aware of the treatment order, reviewed diary card
A, performed spirometry, and recorded asthma exacerba-
tions and adverse events.
Participants were asked to keep all asthma medication,
apart from short-acting bronchodilators, constant
throughout the study unless they had an asthma exacer-
bation, defined in relation to the run-in period as a 20% fall
in FEV1, a fall in PEF of 30% on one day, a 15% fall or
increase of 4 puffs of short-acting bronchodilator on 2
successive days, or asthma needing urgent medical care.
Following an exacerbation participants did not enter the
next treatment phase until at least one week after medi-
cation and PEF had returned to baseline levels.
Endpoints
The primary efficacy variables were mean morning PEF and
symptom scores (Asthma Control Diary)22 in the fourthFigure 1 Consort flowchweek of each treatment period. Secondary outcomes
included evening PEF, diurnal variation in PEF, FEV1, short-
acting bronchodilator use, night-time waking with asthma,
exacerbations, and Nijmegen, Asthma Control and Mini-
Asthma Quality of Life questionnaires. Exacerbations were
classified as mild (increased inhaled corticosteroid for less
than 5 days), moderate (increased inhaled corticosteroid
for at least 5 days), or severe (oral corticosteroid taken).
Acceptability and compliance with taping were assessed at
the end of each period.
Sample size was determined by assuming a within
subject standard deviation for repeat peak flow measure-
ments of 30 l/min. Sixty participants would then provide
90% power to detect a change of 12 l/min in morning peak
flow assuming the data were Normally distributed. Due to
recruitment difficulties only 51 participants were recruited
which reduced the power to 80%.
Analysis
The analysis was on an intention to treat basis with all
participants who had any data for both treatment periods
being included. Carry over and order effects for the primary
outcome measures were measured by independent sample
t-tests. Measurements from the visit at the end of each
treatment period and mean daily diary card data from the
fourth week of each treatment period were compared by
paired t-test for primary and secondary outcomes. A similarart of patients in trial.
Table 1 Baseline characteristics of study participants.
Characteristic nZ 50
Age [years] 53 (12.4)
M/F 18/32
Daily inhaled
corticosteroid dose [mg]
567 (354)
Long-acting bronchodilator
[yes/no]
30/20
Short-acting bronchodilator
[median (IQR) puffs
in last 7 days]
10 (4.3e28)
FEV1 [l] 2.41 (0.80)
FEV1% predicted 86.2 (23.0)
FVC [l] 3.32 (1.02)
Reversibility [%]
(median (IQR))
7 (3.8e15.5)
Wake at night with
wheeze/chest tightness? Never e 6
Few times
a year e 18
Several times a month e 12
Several times a week e 8
Every night e 6
Chest tightness in morning?
Never e 4
Few times a year e 7
Several times a month e 12
Several times
a week e 13
Every day e 14
Smoking history
[never/ex/current]
30/19/1
Pack years [for current
or ex-smokers]
4.4 (3.2)
Morning peak expiratory
flow e last 7 days
of baseline [l/min]
417 (91)
Morning peak expiratory
flow e % predicted
83.1 (16.4)
Asthma control diary score e
last 7 days of baseline
1.29 (0.65)
Night-time breathing route
[self-reported]
Nose e 11
Mouth e 19
Both e 16
Don’t know e 4
Rhinitis None e 12
Seasonal e 14
Perennial e 24
Current rhinitis medication None e 29
Nasal steroid only e 8
Antihistamine only e 9
Both e 4
Nijmegen Questionnaire score 19 (6.7)
(18/50 participants
scored 23)
Data presented as mean (SD) unless otherwise stated.
FEV1Z forced expiratory volume in one second; FVCZ forced
vital capacity; ReversibilityZ change in FEV1 30 min after
400 mg salbutamol.
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breathing at night, was also performed. Outcomes which
were not Normally distributed were analysed by non-para-
metric Wilcoxon test.
Codes were only revealed after all data had been
reviewed and analysed.
Results
Of 66 participants screened, 15 either failed the entry
criteria (12) or withdrew consent (3). Fifty-one participants
were therefore randomised and 50 completed the study
(Fig. 1). One participant withdrew after a hospital admission
for an asthma exacerbation during the washout period and
had no data for mouth taping. Diary card data for weeks
three and four of treatment period 1 were missing for one
participant and week two data were substituted. Another
participant mistakenly used mouth taping for four weeks
during the washout period instead of treatment period 2, so
the washout data were substituted for treatment period 2
data. The 50 participants who completed the study had
a mean (SD) age of 53 (12.4) years and mean predicted FEV1
of 86% (23%). Baseline characteristics can be seen in Table 1.
The median number of nights when participants repor-
ted taping their mouth before going to sleep was 26 out of
28 nights (IQR: 23 to 28). On most occasions the tape was
still in place in the morning (median number of nights
reported still in place 16 (8e23)). On five nights out of 28 it
was in place for more than 3 h but not in the morning, and
on one night for less than 3 h.
There were no carry over or order effects between
treatment periods.
No differences were seen between the usual breathing
and mouth taping periods for the two primary outcomes,
morning peak expiratory flow (mean difference: 1 l/min,
(95% CI: 9 to 7)) and symptom scores from the Asthma
Control Diary (0.12 (0.30 to 0.06)) (Table 2). There were
also no differences in primary outcomes for participants
who reported that they normally breathe mainly through
their mouth at night (nZ 19) (Table 3).
There was also no difference between treatments for
secondary outcome measures including evening peak expi-
ratory flow, diurnal variation in peak expiratory flow
(expressed as PEF amplitude percent mean), short-acting
bronchodilator use, night-time waking with asthma, and
Nijmegen, Asthma Control or Mini-Asthma Quality of Life
questionnaires (Table 2).
Ten participants had mild (three), moderate (three) or
severe (four) exacerbations of their asthma during the
usual breathing period compared with eleven participants
(six mild, two moderate, three severe) during the mouth
taping period. Two participants had exacerbations during
both treatment periods. Forty and 39 participants had no
exacerbations during the usual breathing and mouth taping
periods respectively (pZ 0.76).
When asked about acceptability of mouth taping, 36 of
the 50 participants said that it was very or fairly acceptable
to use, whilst 11 said it was very or fairly unacceptable.
However, when asked whether they would continue to tape
their mouth at night after the study only 11 said yes and 29
said no. The most commonly reported problems or dislikes
about mouth taping were that it was uncomfortable (12),
Table 2 Measurements at the end of each treatment period, with the difference between treatment periods. (nZ 50).
Outcome Usual breathing Mouth tape Difference between
treatment periods
P value
Morning PEF [l/min] 412 (95) 413 (98) 1 (9 to 7) 0.78
Asthma Control Diary scorea: symptoms only 1.03 (0.73) 1.15 (0.92) 0.12 (0.30 to 0.06) 0.19
Asthma Control Diary scorea 1.20 (0.68) 1.30 (0.92) 0.09 (0.25 to 0.06) 0.24
Evening PEF [l/min] 429 (93) 428 (97) 0.04 (7 to 7) 0.99
PEF amplitude percent mean 0.04 (0.08) 0.04 (0.07) 0.00 (0.01 to 0.02) 0.48
Puffs per week short-acting
bronchodilator (median (IQR))
6.5 (1.75e21.75) 9.5 (2 to 25) 3.0 0.12
Night-time waking with asthma
[score from ACD]a (median (IQR))
0 (0e1) 0 (0e1) 0 0.10
FEV1 2.68 (1.20) 2.44 (0.82) 0.24 (0.08 to 0.57) 0.14
Nijmegen Questionnaire scoreb 16 (7) 15 (8) 1.1 (0.4 to 2.6) 0.13
Asthma Control Questionnaire scorea 2.37 (1.33) 2.41 (1.68) 0.03 (0.68 to 0.61) 0.92
Mini-Asthma Quality of Life Questionnaire scorec 5.43 (0.94) 5.33 (1.19) 0.10 (0.14 to 0.34) 0.40
Data presented as mean (SD) and mean (95% CI) unless otherwise stated; PEFZ Peak expiratory flow; ACDZ Asthma Control Diary.
a Asthma Control Diary and Questionnaire: higher scoreZworse asthma control (range 0e6).
b Nijmegen Questionnaire: higher scoreZmore symptoms associated with abnormal breathing patterns (range 0e64, 23 has been
used to indicate hyperventilation).
c Mini-Asthma Quality of Life Questionnaire: higher scoreZ better quality of life (range 1e7).
Effect of mouth taping at night on asthma control 817caused sore lips (14), made breathing more difficult (10),
felt unnatural (11), made sleeping worse (9), caused
a feeling of suffocation (8), or was embarrassing (5). Some
participants however felt that mouth taping improved sleep
quality (11), reduced snoring (16), and left their mouth
fresher on waking (13). Three participants thought mouth
taping made their asthma worse, whilst 13 felt that their
asthma had improved.
Discussion
In this randomised, single-blind, crossover trial most of the
51 participants with symptomatic asthma found mouth
taping at night to be acceptable and compliance appeared
to be good. We found no evidence, however, to suggest that
mouth taping for four weeks has either a positive or nega-
tive effect on asthma control. The same was true for the 19
participants who reported that they breathe mainly
through their mouth at night.
Our study rationale was based on the assumption that
mouth breathing could compromise asthma control. The
nose warms and humidifies inspired air, filters particles and
gaseous materials that may be allergenic or irritant, and
slows flow velocity in the airways, which may reduce fric-
tional resistance and mucosal damage.23 The nose also
provides two thirds of the resistance in the respiratory tractTable 3 Morning peak expiratory flow and symptoms at the end
they breathe mainly through the mouth at night, with the differe
Primary outcome Usual breathing
Morning PEF [l/min] 403 (98)
Asthma Control
Diary score: symptoms only
1.05 (0.56)
Data presented as mean (SD) and mean (95% CI).and an expiratory resistance helps to maintain lung
volume.24
Few studies have looked at the effects of mouth
breathing in patients with asthma. When compared to nasal
breathing, mouth breathing has been associated with a fall
in FEV1,
25 an increase in exercise bronchoconstriction,26,27
and a trend towards lower end-tidal carbon dioxide
levels.28 Conversely, the use of a nasal dilator overnight has
been associated with fewer awakenings due to asthma29
whilst breathing warm, humid air reduced the overnight fall
in FEV1 in patients with nocturnal asthma.
30 Such studies
suggest that patients with asthma may benefit from
breathing through the nose rather than the mouth at night.
It is disappointing therefore that mouth taping at night
to induce nasal breathing did not improve asthma control in
our patients. Reasons for this include the possibility that
the ambient air in the participants’ bedrooms was not
sufficiently cold and dry to cause bronchoconstriction when
they breathed through the mouth. Alternatively the extent
to which our participants breathed through the mouth at
night was insufficient for taping to make a noticeable
difference or adherence with mouth taping was less than
reported. Although it would have been possible to only
study patients with an adverse bedroom environment or
who predominantly mouth breath and we could have
videoed participants to monitor adherence, we wished toof each treatment period for participants who reported that
nce between treatment periods (nZ 19).
Mouth tape Difference between
treatment periods
P value
397 (99) 6 (6 to 17) 0.31
1.34 (0.94) 0.29 (0.68 to 0.10) 0.13
818 S. Cooper et al.perform a pragmatic study to determine whether mouth
taping has any beneficial effects in a general population of
patients with symptomatic asthma. The tight confidence
limits around our results suggest that there are unlikely to
be subgroups of responders and, by implication, that the
intervention is not able to affect asthma control.
The nocturnal breathing pattern of peoplewith asthmahas
not beendetermined and surprisingly little is known about the
extent to which healthy subjects breathe through the nose or
mouth at night. It is difficult to measure breathing route
without disturbing breathing patterns31e33 and we do not
have this information in our participants. The limited data on
nocturnal breathing patterns in non-asthmatic subjects
suggest that for most subjects more ventilation occurs
through the nose than through themouth.34e38 Since subjects
with asthma are more likely than healthy volunteers to
breathe through the mouth when awake39,40 and switch more
readily to oral breathing with increasing respiratory load40,41
it is likely that they breathe through the mouth more often at
night.
In summary, despite good reasons to hypothesise that
nose breathing at night could be beneficial, our study has
shown that taping the mouth at night has no effect on
asthma control when used in patients with symptomatic
asthma. Our results may not pertain to situations where the
air in the bedroom is colder and drier, where asthma is very
severe, or when used as part of the Buteyko technique.
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